Skeletal effects of interventions in mild primary hyperparathyroidism: A meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 4, 2010, Pages 1653-1662

  Sankaran, Shyam ^a   Gamble, Greg ^a   Bolland, Mark ^a   Reid, Ian R ^a   Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; COCHRANE LIBRARY; DUAL ENERGY X RAY ABSORPTIOMETRY; EMBASE; FEMALE; HUMAN; HYPERPARATHYROIDISM; MALE; MEDLINE; META ANALYSIS; OSTEOLYSIS; PRIORITY JOURNAL; BLOOD; BONE; BONE DEVELOPMENT; CLINICAL TRIAL; DENSITOMETRY; FOLLOW UP; HORMONE SUBSTITUTION; MIDDLE AGED; PARATHYROIDECTOMY; PATHOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; BONE RESORPTION; CALCIUM; CLINICAL TRIALS AS TOPIC; DENSITOMETRY; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; PARATHYROID HORMONE; PARATHYROIDECTOMY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77951644522     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2384     Document Type: Article

References (73)

1. Mihai R, Wass JA, Sadler GP 2008 Asymptomatic hyperparathyroidism - need for multicentre studies. Clin Endocrinol (Oxf) 68:155-164
2. Toft AD 2000 Surgery for primary hyperparathyroidism - sooner rather than later. Lancet 355:1478-1479
3. Grey AB 1997 The skeletal effects of primary hyperparathyroidism. Baillieres Clin Endocrinol Metab 11:101-116
4. Khan AA, Bilezikian JP, Potts Jr JT 2009 The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab 94:333-334
5. Davies M, Fraser WD, Hosking DJ 2002 The management of primary hyperparathyroidism. Clin Endocrinol (Oxf) 57:145-155
6. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV 1989 Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283-291
7. Grey AB, Evans MC, Stapleton JP, Reid IR 1994 Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. Ann Intern Med 121:745-749
8. Khosla S, Melton 3rd LJ, Wermers RA, Crowson CS, O'Fallon W, Riggs B 1999 Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14:1700-1707 (Pubitemid 29455818)
9. Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L 2000 Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321:598-602
10. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, McMahon DJ, Bilezikian JP 1995 Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab 80:729-734
11. Steiniche T, Christiansen P, Vesterby A, Ullerup R, Hessov I, Mosekilde LE, Melsen F 2000 Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone 26:535-543
12. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA 2004 Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:3319-3325
13. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, Lo KW, Cockram CS 2003 Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88:581-587 (Pubitemid 36207794)
14. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR 1996 Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 125:360-368
15. Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R 1996 Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 81:3487-3491
16. Diamond T, Ng AT, Levy S, Magarey C, Smart R 1996 Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report. Osteoporos Int 6:329-333 (Pubitemid 26280829)
17. Fraser WD 2009 Hyperparathyroidism. Lancet 374:145-158
18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB 2000 Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008-2012
19. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF 1999 Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896-1900
20. Rao C 1973 Linear statistical inference and its applications. New York: Wiley and Sons
21. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, Bilezikian JP 1995 Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 80:723-728
22. Thorsen K, Kristoffersson AO, Lorentzon RP 1997 Changes in bone mass and serum markers of bone metabolism after parathyroidectomy. Surgery 122:882-887
23. Abdelhadi M, Nordenström J 1998 Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 83:3845-3851 (Pubitemid 28513560)
24. Fuliehan GE, Moore Jr F, LeBoff MS, Hurwitz S, Gundberg CM, Angell J, Scott J 1999 Longitudinal changes in bone density in hyperparathyroidism. J Clin Densitom 2:153-162
25. Gonnelli S, Montagnani A, Cepollaro C, Monaco R, Gennari L, Rossi B, Pacini S, Gennari C 2000 Quantitative ultrasound and bone mineral density in patients with primary hyperparathyroidism before and after surgical treatment. Osteoporos Int 11:255-260
26. Kanzawa M, Sugimoto T, Kobayashi T, Kobayashi A, Chihara K 2000 Association between parathyroid hormone (PTH)/PTH-related peptide receptor gene polymorphism and the extent of bone mass reduction in primary hyperparathyroidism. Horm Metab Res 32:355-358
27. Nakaoka D, Sugimoto T, Kobayashi T, Yamaguchi T, Kobayashi A, Chihara K 2000 Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 85:1901-1907 (Pubitemid 32269296)
28. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S 2001 Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 16:113-119
29. Horiuchi T, Onouchi T, Inoue J, Shionoiri A, Hosoi T, Orimo H 2002 A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy. Gerontology 48:103-108
30. Ingle BM, Thomas WE, Eastell R, Thomas WEG 2002 Differential effects of primary hyperparathyroidism on ultrasound properties of bone. Osteoporos Int 13:572-578
31. Lumachi F, Ermani M, Basso SM, Camozzi V, Nardi A, Favia G, Luisetto G, Basso SMM 2003 Short- and long-term changes in bone mineral density of the lumbar spine after parathyroidectomy in patients with primary hyperparathyroidism. Calcif Tissue Int 73:44-48
32. Nomura R, Sugimoto T, Tsukamoto T, Yamauchi M, Sowa H, Chen Q, Yamaguchi T, Kobayashi A, Chihara K 2004 Marked and sustained increase in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism; a six-year longitudinal study with or without parathyroidectomy in a Japanese population. Clin Endocrinol (Oxf) 60:335-342
33. Stilgren LS, Hegedüs LM, Beck-Nielsen H, Abrahamsen B 2003 Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif Tissue Int 73:210-216 (Pubitemid 37152880)
34. Nordenström E, Westerdahl J, Bergenfelz A 2004 Recovery of bone mineral density in 126 patients after surgery for primary hyperparathyroidism. World J Surg 28:502-507
35. Sitges-Serra A, Girvent M, Pereira JA, Jimeno J, Noguës X, Cano FJ, Sancho JJ 2004 Bone mineral density in menopausal women with primary hyperparathyroidism before and after parathyroidectomy. World J Surg 28:1148-1152
36. Lumachi F, Camozzi V, Ermani M, Nardi A, Luisetto G 2007 Lumbar spine bone mineral density changes in patients with primary hyperparathyroidism according to age and gender. Skeletal biology and medicine, Part B: disease mechanisms and therapeutic challenges. Ann NY Acad Sci 1117:362-366
37. Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L 2008 Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) 68:707-715
38. Ayturk S, Gursoy A, Bascil Tutuncu N, Ertugrul DT, Guvener Demirag N 2006 Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 91:4260-4263
39. Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K 2002 Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 87:4946-4951
40. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, Varhaug JE, Baranowski M, Aanderud S, Franco C, Freyschuss B, Isaksen GA, Ueland T, Rosen T 2007 Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 92:1687-1692
41. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, Oppo A, Miccoli P, Berti P, Bilezikian JP, Pinchera A, Marcocci C 2007 Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92:3114-3121
42. Rao DS, Phillips ER, Divine GW, Talpos GB 2004 Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89:5415-5422
43. Almqvist EG, Becker C, Bondeson AG, Bondeson L, Svensson J 2004 Early parathyroidectomy increases bone mineral density in patients with mild primary hyperparathyroidism: a prospective and randomized study. Surgery 136:1281-1288
44. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ 2002 Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 87:4482-4489
45. Hassani S, Braunstein GD, Seibel MJ, Brickman AS, Geola F, Pekary AE, Hershman JM 2001 Alendronate therapy of primary hyperparathyroidism. Endocrinologist 11:459-464
46. Bolland MJ, Grey AB, Orr-Walker BJ, Horne AM, Evans MC, Clearwater JM, Gamble GD, Reid IR 2008 Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism. N Z Med J 121:18-29
47. Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR 2000 Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 160:2161-2166 (Pubitemid 30482723)
48. Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Heickendorff L, Mosekilde L 1999 Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study. Bone 25:589-595 (Pubitemid 29469466)
49. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249-1255
50. Cormier C, Ruiz JC, Ledevic P, Galimard E, Luton JP 1994 Bone repair after parathyroidectomy in primary hyperparathyroidism. J Bone Miner Res 9:S422 (Abstract)
51. Debiais F, Kraimps J, Bounard M, Marechaud R, Ingrand P, Azais I, Brault R, Alcalay M 2004 Changes in biochemical bone markers and bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Bone Miner Res 19:S325 (Abstract)
52. Marcocci C, Cianferotti L, Vignali E, Picone S, Puccinelli S, Golia F, Ciampi M, Miccoli P, Pinchera 1997 A recovery of bone mass after successful parathyroidectomy for primary hyperparathyroidism. J Bone Miner Res 12:S517 (Abstract)
53. Lumachi F, Luisetto G, Nardi A, Camozzi V, Masiero V, Favia G 2001 Femoral and lumbar spine BMD changes in patients with primary hyperparathyroidism: different improvements following successful parathyroidectomy in male and female patients. Bone 28:S113 (Abstract)
54. Chappard C, Roux C, Paillard M, Houillier P 2001 Predicting factors of BMD variations induced by parathyroidectomy in primary hyperparathyroidism. J Bone Miner Res 16:S458 (Abstract)
55. Rao D, Philips E, Jacobsen G, Divine G 1994 Natural history of untreated mild primary hyperparathyroidism (PHPT); first 5 year results of a prospective clinical study. J Bone Miner Res 9:S423 (Abstract)
56. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D 2005 Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135-141
57. Kenny AM, MacGillivray DC, Pilbeam CC, Crombie HD, Raisz LG 1995 Fracture incidence in postmenopausal women with primary hyperparathyroidism. Surgery 118:109-114
58. Vestergaard P, Mosekilde L 2003 Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 327:530-534
59. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, The Osteoporosis Methodology G, The Osteoporosis Research Advisory G 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578
60. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med3 56:1809-1822 (Pubitemid 46698462)
61. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
62. Reid IR, Ames R, Mason B, Reid HE, Bacon CJ, Bolland MJ, Gamble GD, Grey A, Horne A 2008 Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med 168:2276-2282
63. Reid IR, Mason B, Horne A, Ames R, Reid HE, Bava U, Bolland MJ, Gamble GD 2006 Randomized controlled trial of calcium in healthy older women. Am J Med 119:777-785
64. Grey AB, Stapleton JP, Evans MC, Reid IR 1996 Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism. Clin Endocrinol (Oxf) 44:697-702
65. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM 1988 Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 67:1294-1298 (Pubitemid 19012967)
66. Bolland MJ, Grey AB, Gamble GD, Reid IR 2005 Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab 90:1525-1530
67. Wu F, Ames R, Clearwater J, Evans MC, Gamble G, Reid IR 2002 Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. Clin Endocrinol (Oxf) 56:703-711
68. Patel R, Blake GM, Rymer J, Fogelman I 2000 Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int 11:68-75
69. Compston J 2009 Monitoring bone mineral density during antiresorptive treatment for osteoporosis. BMJ 338:b1276
70. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199
71. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
72. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ 2008 The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462-3470
73. Iskander J, Rao D 2007 Long term morbidity and mortality in untreated mild primary hyperparathyroidism. J Bone Miner Res 22:S353 (Abstract)